Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of cenicriviroc for liver fibrosis in adults with nonalcoholic steatohepatitis
MOH_2020-01-07_008596Phase 2Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cenicriviroc in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis, sponsored by AbbVie Inc. Primary endpoint: Long-term safety and tolerability of cenicriviroc. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
cenicriviroc
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on MOH_2020-01-07_008596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-07_008596.